Mechanical airway clearance using the Frequencer electro-acoustical transducer in cystic fibrosis

Cantin, AndreƩ M.; Bacon, Mare; Berthiaume, Yves
June 2006
Clinical & Investigative Medicine;Jun2006, Vol. 29 Issue 3, p159
Academic Journal
Purpose. Clearance of mucus from airways is the cornerstone of therapy for lung disease in patients with cystic fibrosis (CF). This paper describes the operation of the Frequencer, a novel respiratory physiotherapy device comprised of an electro-acoustical transducer. We hypothesized that the Frequencer would be a safe and effective therapy to help clear secretions from the airways of subjects with CF. Methods. To verify this hypothesis, 22 individuals with CF were recruited to this study comparing sputum production during conventional chest physiotherapy (CCPT) mad Frequencer therapy using a crossover design. The sputum weight was the main outcome measure. Results. Sputum weight was found to be a reproducible measure of the efficacy of chest physiotherapy in individual patients. The Frequencer induced airway clearance in patients with CF that was equivalent to that of CCPT. Furthermore, treatment of a 4% mucin preparation ex vivo with the Frequencer significantly reduced the viscosity of the mucin solution as determined ha a capillary rheometer. Conclusions. These results indicate the Frequencer is safe and as effective as CCPT in inducing airway clearance in patients with CF.


Related Articles

  • DISCOVERY AEROSOLIZED KL-4 SURFACTANT SELECTED FOR PHASE 2A.  // Biotech Business;Oct2008, Vol. 21 Issue 10, p6 

    The article reports that Discovery Laboratories, Inc. has announced that its proprietary, aerosolized KL-4 surfactant has been selected for a Phase 2a clinical trial in patients with Cystic Fibrosis (CF). This trial is designed to evaluate the safety and tolerance in patients with mild to...

  • Improving rate of decline of FEY1 in young adults with cystic fibrosis. Que, C.; Cullinan, P.; Geddes, D. // Thorax;Feb2006, Vol. 61 Issue 2, p155 

    Background: CF is characterised by a progressive decline in lung function; reductions in this decline are often used as a measure of success in clinical trials. With improvements in treatment it may be that there has been a temporal shift in the pattern of the disease. Methods: 318 patients born...

  • tgAAVCF: will Phase II failure be the straw that breaks investors' backs?  // PharmaWatch: Monthly Review;May2005, Vol. 4 Issue 5, p21 

    The article reports on the failure of the phase II clinical trial of the Targeted Genetics' proprietary adeno-associated virus vector cystic fibrosis (tgAAVCF) therapy in the U.S. The phase II clinical trials reveals that it had failed to improve lung function in patients with mild to moderate...

  • Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial. C Minasian // Thorax;Jan2010, Vol. 65 Issue 1, p51 

    BACKGROUND: Osmotic agents, such as inhaled dry powder mannitol, may increase mucociliary clearance by rehydrating the airway surface liquid and thus act as disease-modifying treatments in cystic fibrosis (CF). This is the first therapeutic trial of inhaled mannitol in children with CF; it was...

  • Gene modifiers in cystic fibrosis. Accurso, Frank J.; Sontag, Marci K. // Journal of Clinical Investigation;Mar2008, Vol. 118 Issue 3, p839 

    Studies of modifier genes in cystic fibrosis (CF) have often been performed in small or narrowly defined populations, leading to conflicting results. In this issue of the JCI, Dorfman et al. demonstrate in a large, population-based study that two previously studied modifier genes, coding for...

  • Effect of Including Important Clinical Variables on Accuracy of the Lung Allocation Score for Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. Lehr, Carli J.; Skeans, Melissa; Dasenbrook, Elliott; Fink, Aliza; Fernandez, Gabriela; Faro, Albert; Valapour, Maryam; Dasenbrook, Elliot C // American Journal of Respiratory & Critical Care Medicine;10/15/2019, Vol. 200 Issue 8, p1013 

    Rationale: Clinical variables associated with shortened survival in patients with advanced-stage cystic fibrosis (CF) are not included in the lung allocation score (LAS).Objectives: To identify variables associated with wait-list and post-transplant mortality for CF lung transplant candidates...

  • What Is Cystic Fibrosis? Knowles, Michael R.; Durie, Peter R. // New England Journal of Medicine;8/8/2002, Vol. 347 Issue 6, p439 

    Editorial. Offers observations on cystic fibrosis. Definition of cystic fibrosis; How to cope with the diagnostic challenges posed by nonclassic cystic fibrosis; Reference to an article in this issue by Groman et al; Limitations of this study; Difficulty of determining whether patients have a...

  • Variant Cystic Fibrosis Phenotypes in the Absence of CFTR Mutations. Groman, Joshua D.; Meyer, Michelle E.; Wilmott, Robert W.; Zeitlin, Pamela L.; Cutting, Garry R. // New England Journal of Medicine;8/8/2002, Vol. 347 Issue 6, p401 

    Background: Cystic fibrosis is a life-limiting autosomal recessive disorder with a highly variable clinical presentation. The classic form involves characteristic findings in the respiratory tract, gastrointestinal tract, male reproductive tract, and sweat glands and is caused by...

  • Physiologic Evidence for the Efficacy of Positive Expiratory Pressure as an Airway Clearance Technique in Patients With Cystic Fibrosis. Darbee, Joan C.; Ohtake, Patricia J.; Grant, Brydon JB; Cerny, Frank J. // Physical Therapy;Jun2004, Vol. 84 Issue 6, p524 

    Background and Purpose. Individuals with cystic fibrosis (CF) have large amounts of infected mucus in their lungs, which causes irreversible lung tissue damage. Although patient-administered positive expiratory pressure (PEP) breathing has been promoted as an effective therapeutic modality for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics